These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 22374717

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.
    Li X, Zhang L, Chen X, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Xu Q, Zhang Y, Li Y, Lu C, Yin T.
    Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903
    [Abstract] [Full Text] [Related]

  • 3. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A.
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [Abstract] [Full Text] [Related]

  • 4. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, Scott SA, Montalescot G.
    Circ Cardiovasc Interv; 2011 Oct 01; 4(5):422-8. PubMed ID: 21972404
    [Abstract] [Full Text] [Related]

  • 5. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
    Tresukosol D, Suktitipat B, Hunnangkul S, Kamkaew R, Poldee S, Tassaneetrithep B, Likidlilid A.
    PLoS One; 2014 Oct 01; 9(10):e110188. PubMed ID: 25329996
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects.
    Chan MY, Tan K, Tan HC, Huan PT, Li B, Phua QH, Lee HK, Lee CH, Low A, Becker RC, Ong WC, Richards MA, Salim A, Tai ES, Koay E.
    Pharmacogenomics; 2012 Apr 01; 13(5):533-42. PubMed ID: 22462746
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
    Zhang L, Chen Y, Jin Y, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Li X, Li Y, Zhang Y, Lu C, Yin T.
    Thromb Res; 2013 Jul 01; 132(1):81-7. PubMed ID: 23726091
    [Abstract] [Full Text] [Related]

  • 12. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD.
    J Am Coll Cardiol; 2013 Feb 26; 61(8):872-9. PubMed ID: 23333143
    [Abstract] [Full Text] [Related]

  • 13. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
    Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, Dubar M.
    Clin Pharmacol Ther; 2011 Aug 26; 90(2):287-95. PubMed ID: 21716274
    [Abstract] [Full Text] [Related]

  • 14. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
    Braun OÖ, Angiolillo DJ, Ferreiro JL, Jakubowski JA, Winters KJ, Effron MB, Duvvuru S, Costigan TM, Sundseth S, Walker JR, Saucedo JF, Kleiman NS, Varenhorst C.
    Thromb Haemost; 2013 Dec 26; 110(6):1223-31. PubMed ID: 24009042
    [Abstract] [Full Text] [Related]

  • 15. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
    Cano P, Consuegra-Sánchez L, Conesa P, Torres-Moreno D, Jaulent L, Dau D, Picó F, Villegas M.
    Med Clin (Barc); 2014 Jul 07; 143(1):6-12. PubMed ID: 23850044
    [Abstract] [Full Text] [Related]

  • 16. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
    Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A.
    Drug Metab Dispos; 2010 Jan 07; 38(1):92-9. PubMed ID: 19812348
    [Abstract] [Full Text] [Related]

  • 17. Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity.
    Oh J, Shin D, Lim KS, Lee S, Jung KH, Chu K, Hong KS, Shin KH, Cho JY, Yoon SH, Ji SC, Yu KS, Lee H, Jang IJ.
    Clin Pharmacol Ther; 2014 Jun 07; 95(6):608-16. PubMed ID: 24566733
    [Abstract] [Full Text] [Related]

  • 18. Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.
    Zahno A, Brecht K, Bodmer M, Bur D, Tsakiris DA, Krähenbühl S.
    Br J Pharmacol; 2010 Sep 07; 161(2):393-404. PubMed ID: 20735423
    [Abstract] [Full Text] [Related]

  • 19. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A, Ando H, Asai T, Ishiguro H, Umemoto N, Ohta M, Morishima M, Sumida A, Kobayashi T, Hosohata K, Ushijima K, Fujimura A.
    Clin Pharmacol Ther; 2011 Feb 07; 89(2):229-33. PubMed ID: 21178986
    [Abstract] [Full Text] [Related]

  • 20. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.
    Kim KA, Park PW, Hong SJ, Park JY.
    Clin Pharmacol Ther; 2008 Aug 07; 84(2):236-42. PubMed ID: 18323861
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.